Klaus Ort’s Post

View profile for Klaus Ort, graphic

Europe West Industry Market Leader for LifeSciences and HealthCare bei EY

Did you know that the German biotech industry recently recorded the largest M&A transaction in it's history?   ✍ In February 2024, MorphoSys signed an agreement with Novartis to be acquired for €2,7b with shareholders benefitting from a 94% premium   ...and that’s not all: The first quarter of 2024 also saw the most valuable M&A exit of a private German biotech company since 2020:    ✍ Cardior Pharmaceuticals from Hannover agreed to be acquired by Novo Nordisk for €1b   These success stories set an end to the muted M&A market and once again underscore the innovation power and international attractiveness of the German biotechnology industry.   Stay tuned for the upcoming EY German Biotech Report 2024, which will provide a comprehensive analysis of the industry's performance, along with insights into opportunities, challenges, the financing cycle and the most ground-breaking technologies.   In the meantime, join us at the upcoming Deutsche Biotechnologie-Tage, taking place on April 16 and 17 in Berlin. This event will be a great opportunity to connect and discuss the latest trends and developments of the biotech industry. We look forward to seeing you there!   Klaus Ort Dr. Kordula Becker Ulrike Kappe   #DBT2024 #Biotechnologie #Biotech

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics